{"id":7821,"date":"2021-05-04T05:36:24","date_gmt":"2021-05-04T05:36:24","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2\/"},"modified":"2021-05-04T05:36:24","modified_gmt":"2021-05-04T05:36:24","slug":"nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2\/","title":{"rendered":"Nicox : Lancement de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire Bausch + Lomb &#8211; Approbation de VYZULTA\u00ae au Qatar"},"content":{"rendered":"<p>Sophia Antipolis, France<\/p>\n<p><strong>\u00a0<\/strong><strong>Nicox SA<\/strong> (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce le lancement commercial de VYZULTA<sup>\u00ae<\/sup> (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire mondial exclusif Bausch + Lomb, une soci\u00e9t\u00e9 leader mondial en sant\u00e9 oculaire de Bausch Health Companies Inc. L\u2019approbation r\u00e9glementaire de mise sur le march\u00e9 de VYZULTA \u00e0 Taiwan a \u00e9t\u00e9 obtenue en mars 2020. Bausch + Lomb a \u00e9galement r\u00e9cemment re\u00e7u l\u2019approbation de mise sur le march\u00e9 de VYZULTA au Qatar.<\/p>\n<p>Outre Taiwan, VYZULTA est commercialis\u00e9 aux Etats-Unis (2017), au Canada (2019), en Argentine (2020), au Mexique (2020) et \u00e0 Hong Kong (2020).et est approuv\u00e9 dans cinq autres territoires (le Br\u00e9sil, la Colombie, la Cor\u00e9e du Sud, le Qatar et l\u2019Ukraine). VYZULTA est indiqu\u00e9 pour la r\u00e9duction de la pression intraoculaire chez les patients atteints de glaucome \u00e0 angle ouvert ou d&rsquo;hypertension oculaire aux Etats-Unis et dans d\u2019autres territoires pour la m\u00eame indication. Bausch + Lomb poursuit la soumission de demandes d\u2019approbation dans des territoires o\u00f9 les donn\u00e9es cliniques de l\u2019enregistrement am\u00e9ricain peuvent \u00eatre utilis\u00e9es pour approbation par les autorit\u00e9s r\u00e9glementaires locales.<\/p>\n<p>Selon les termes de l\u2019accord de concession de licence exclusif avec Bausch + Lomb, Nicox re\u00e7oit des redevances croissantes de 6% \u00e0 12% sur les ventes nettes mondiales de VYZULTA et des paiements d\u2019\u00e9tape potentiels pouvant atteindre un montant de 150 millions de dollars.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sophia Antipolis, France \u00a0Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce le lancement commercial de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire mondial exclusif Bausch + Lomb, une soci\u00e9t\u00e9 leader mondial en sant\u00e9 oculaire de Bausch Health Companies Inc. L\u2019approbation r\u00e9glementaire de mise [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-7821","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox : Lancement de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire Bausch + Lomb - Approbation de VYZULTA\u00ae au Qatar - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox : Lancement de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire Bausch + Lomb - Approbation de VYZULTA\u00ae au Qatar - Nicox\" \/>\n<meta property=\"og:description\" content=\"Sophia Antipolis, France \u00a0Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce le lancement commercial de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire mondial exclusif Bausch + Lomb, une soci\u00e9t\u00e9 leader mondial en sant\u00e9 oculaire de Bausch Health Companies Inc. L\u2019approbation r\u00e9glementaire de mise [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-04T05:36:24+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox : Lancement de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire Bausch + Lomb &#8211; Approbation de VYZULTA\u00ae au Qatar\",\"datePublished\":\"2021-05-04T05:36:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2\\\/\"},\"wordCount\":260,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2\\\/\",\"name\":\"Nicox : Lancement de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire Bausch + Lomb - Approbation de VYZULTA\u00ae au Qatar - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2021-05-04T05:36:24+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox : Lancement de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire Bausch + Lomb - Approbation de VYZULTA\u00ae au Qatar - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox : Lancement de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire Bausch + Lomb - Approbation de VYZULTA\u00ae au Qatar - Nicox","og_description":"Sophia Antipolis, France \u00a0Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce le lancement commercial de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire mondial exclusif Bausch + Lomb, une soci\u00e9t\u00e9 leader mondial en sant\u00e9 oculaire de Bausch Health Companies Inc. L\u2019approbation r\u00e9glementaire de mise [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2\/","og_site_name":"Nicox","article_published_time":"2021-05-04T05:36:24+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2\/"},"author":{"name":"","@id":""},"headline":"Nicox : Lancement de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire Bausch + Lomb &#8211; Approbation de VYZULTA\u00ae au Qatar","datePublished":"2021-05-04T05:36:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2\/"},"wordCount":260,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2\/","url":"https:\/\/www.nicox.com\/fr\/nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2\/","name":"Nicox : Lancement de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024% \u00e0 Taiwan par son partenaire Bausch + Lomb - Approbation de VYZULTA\u00ae au Qatar - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2021-05-04T05:36:24+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-lancement-de-vyzulta-solution-ophtalmique-de-latanoprostene-bunod-0024-a-taiwan-par-son-partenaire-bausch-lomb-approbation-de-vyzulta-au-qatar-2\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7821"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7821\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}